利用优化的靶向二代测序进行临床诊断,在日本卵巢透明细胞癌患者中鉴定新突变
本研究优化并评估了基于福尔马林固定石蜡包埋(FFPE)样本的409个癌症相关基因外显子组分析,用于日本卵巢透明细胞癌(OCCC)的体细胞突变检测。29对匹配样本中18对(63%)FFPE DNA质量合格,鉴定出34个基因的45个体细胞突变,其中PIK3CA突变最常见(28%)。研究证明利用靶向二代测序(NGS)对OCCC FFPE样本进行临床诊断是可行的。
要点
- 29对OCCC样本中18对(63%)FFPE DNA符合NGS质量要求
- 鉴定出34个基因的45个体细胞突变,PIK3CA突变最常见(28%)
- 7个基因在至少两个独立OCCC中发生突变
核心结论
- 研究成功鉴定了日本OCCC中的新基因变异,并证明利用靶向NGS对OCCC FFPE样本进行临床诊断是可行的。
研究设计与样本
- 研究优化并评估了基于FFPE和新鲜冷冻(FF)DNA的409个癌症相关基因外显子分析,并对NGS数据进行分析以鉴定日本OCCC中的体细胞突变。
- 从29对匹配的正常和OCCC样本中,18对(63%)FFPE样本提取了足够且质量良好的DNA用于NGS(FIGO I期:12对)。
主要发现
- 提取DNA的质量取决于储存时间长度(<2年储存)。
- 从FFPE DNA中鉴定出34个基因的45个体细胞突变,包括未报道的变异,其中PIK3CA基因体细胞突变最常见(28%),与既往报道一致。
- 7个基因(PIK3CA、ARID1A、CTNNB1、CSMD3、LPHN3、LRP1B和TP53)在至少两个独立OCCC中发生突变。
- 18例OCCC中有3例可获得FF样本,14个FFPE体细胞突变中13个得到确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Ovarian clear cell carcinoma (OCCC) is an aggressive ovarian cancer with a higher frequency in Japan and often becomes chemorefractory disease. Reliable genetic diagnosis is essential to affirm the success of precision medicine for OCCC treatment. The aim of this study is, therefore, to identify novel mutations in OCCCs and develop a feasible clinical next generation sequencing (NGS) approach using formalin-fixed paraffin-embedded (FFPE) rather than preferable but not always available fresh frozen (FF) samples. METHODS: We optimized and evaluated exome analyses of 409 cancer-related genes using FFPE and FF DNA and analyzed NGS data to identify somatic mutations in Japanese OCCCs. RESULTS: Sufficient and good quality DNAs from FFPE samples were extracted from 18 (FIGO Stage I: 12) out of 29 pairs of matched normal and OCCC for NGS (63%). The fine quality of extracted DNAs depended on the length of storage period (<2years storage). We also identified 45 somatic mutations in 34 genes including unreported variants from those FFPE DNA, in which somatic mutations in the PIK3CA gene was the most common (28%) as previously reported. Seven genes (PIK3CA, ARID1A, CTNNB1, CSMD3, LPHN3, LRP1B, and TP53) were mutated in at least two independent OCCCs. FF samples from 3 out of those 18 OCCCs were available and 13 out of 14 FFPE somatic mutations were confirmed. CONCLUSIONS: We successfully identified novel genetic alterations in Japanese OCCCs and demonstrated a feasible clinical diagnostic procedure using targeted NGS for OCCC FFPE samples.
引用
- Maru Y, Tanaka N, Ohira M, et al. Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis. Gynecol Oncol. 2016. PMID: 27939411. doi:10.1016/j.ygyno.2016.11.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。